Bionomics (NASDAQ:BNOX) Shares Up 4.2% – What’s Next?

Bionomics Limited (NASDAQ:BNOX)’s share price traded up 4.2% during trading on Friday . The company traded as high as $0.29 and last traded at $0.25. 6,835,891 shares changed hands during mid-day trading, an increase of 140% from the average session volume of 2,848,698 shares. The stock had previously closed at $0.24.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Bionomics in a research note on Friday, November 15th.

Bionomics Stock Up 4.2 %

The company’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.47.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC purchased a new stake in Bionomics Limited (NASDAQ:BNOX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned about 15.03% of Bionomics at the end of the most recent quarter. Hedge funds and other institutional investors own 15.90% of the company’s stock.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.